|
|
Vioxx Recall: The
international prescription drug company
Merck announced in September 2004 the worldwide
withdrawal of the arthritis medication Rofecoxib,
sold in most countries under the brand name
Vioxx, because a study showed an increased
risk of heart attack and stroke.
Vioxx
Trial: Patients
who have suffered injuries due to Vioxx
have filed litigation against Merck for
selling Vioxx even though Merck allegedly
was aware of Vioxx's dangerous
side effects. |
|
|
|
| |
|
FDA
Public Health Advisory: Safety of Vioxx
|
| |
| September 30, 2004 -- Merck & Co., Inc. today announced
a voluntary withdrawal of Vioxx from the U.S. market due
to safety concerns. Vioxx is a prescription COX-2 selective,
non-steroidal anti-inflammatory drug (NSAID) that was
approved by FDA in May 1999 for the relief of the signs
and symptoms of osteoarthritis, for the management of
acute pain in adults, and for the treatment of menstrual
symptoms. It is also approved for the relief of the signs
and symptoms of rheumatoid arthritis in adults and children. |
| The
Agency was informed by Merck & Co., Inc. on September
27, 2004, that the Data Safety Monitoring Board for an ongoing long-term study
of Vioxx (APPROVe) had recommended that the study be stopped early for safety
reasons. The study was being conducted in patients at risk for developing
recurrent colon polyps. |
| The study showed an increased risk of cardiovascular
events (including heart attack and stroke) in patients on Vioxx compared to placebo,
particularly those who had been taking the drug for longer than 18 months. Based
on this new safety information, Merck and FDA officials met the next day, September
28, 2004, and during that meeting FDA was informed that Merck was voluntarily
withdrawing Vioxx from the market place. |
| The
risk that an individual patient taking Vioxx will suffer
a heart attack or stroke related to the drug is very small.
Patients who are currently taking Vioxx should contact
their physician for guidance regarding discontinuation
and alternative therapies. |
| The
FDA is working closely with Merck to coordinate the withdrawal
of this product from the U.S. market place. Healthcare
professionals are advised to contact Merck at 1-888-368-4699
or at www.merck.com
or at the FDA’s Drug Information Office at 301-827-4573
or 1-888-463-6332 or go to Vioxx Information on FDA’s
website at: www.fda.gov/cder/drug/infopage/vioxx/default.gov
for questions about this product. |
| Lieff Cabraser: Experienced Product Liability Lawyers |
| Founded in 1972, Lieff Cabraser Heimann & Bernstein,
LLP is an over fifty attorney law firm with offices in San Francisco, New
York and Nashville. For the last five years, the National Law Journal has
recognized Lieff Cabraser as one of the top plaintiffs’ law firms
in America. |
| For our personal injury cases, we bring a team of experienced lawyers. Each client is assigned a partner and an associate. In addition, we have on staff multiple nurses, legal assistants, scientific analysts and case clerks to assist the attorneys. |
| We have represented thousands of patients who ingested prescription drugs with dangerous undisclosed side effects, and patients who received defective medical devices in personal injury lawsuits across America, including residents of Alaska, Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Montana, North Carolina, North Dakota, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, Wisconsin, West Virginia and Wyoming. |
|
| Notice
on Practice and Statute of Limitations |
| Lieff
Cabraser attorneys provide legal advice and practice law
for clients in federal district courts throughout the
United States and in state courts where we are licensed
to practice. In states in which our lawyers are not licensed
to practice, we have affiliations with local attorneys
who serve as co-counsel with our firm. Please read our
Disclaimer. |
| Persons
seeking to preserve any potential legal claims for allegedly
dangerous and/or defective products should contact an
attorney promptly because all states have mandatory time
periods (called "statutes of limitation") within
which lawsuits must be filed. Otherwise, a person's claims
may be forever barred. In some states, the statute of
limitations period for filing personal injury claims is
only one year from the date of injury. |
|
|
|
|
|
Lieff
Cabraser Heimann & Bernstein, LLP
|
|
|
|
|
|
|
| Trademark Notice |
| "Vioxx" is
a registered trademark of Merck. Lieff Cabraser Heimann & Bernstein,
LLP is in no way affiliated with Merck, and the Vioxx
trademark is used solely for informational purposes. |
|
|
|
Copyright © 2007 Lieff Cabraser Heimann & Bernstein, LLP |
| |
|
|
Merck
Agrees to Resolve U.S. VIOXX® Product
Liability Lawsuits
November 9, 2007
Merck & Co., Inc.
announced that
it has entered into
an agreement to resolve
state and federal myocardial
infarction (MI) and
ischemic stroke claims
already filed against
the Company in the
United States. More... |
|
|
|
|